Chemotherapy with bevacizumab, irinotecan, 5-fluorouracil and leucovorin (IFL) associated with a large, embolizing thrombus in the thoracic aorta
Authors:
Open Access
- 1 December 2006
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 17 (12) , 1851-1852
Abstract
We read with interest the studies [1–3] and the review by Midgley and Kerr [4] on the role of bevacizumab in the therapy of metastatic cancers. We report on a new presentation of arterial thrombo-embolism that occurred during chemotherapy with bevacizumab and irinotecan, 5-fluorouracil and leucovorin (IFL). A 57-year-old man with a history of rectal amputation from distal rectum cancer stage I (pT2NoMoG1) 6 years ago, was admitted with respiratory symptoms. Thoracic CT scan (including CT-guided biopsies) showed three lung metastases of the previous rectal cancer. This otherwise healthy patient was a non-smoker without cardiovascular risk factors. The laboratory work-up showed normal values. Palliative first-line chemotherapy with bevacizumab (5 mg/kg every 2 weeks) and IFL was started (irinotecan 125 mg/m2 i.v., 5-fluoruracil 500 mg/m2 i.v. and leucovorin 20 mg/m2 i.v. given once a week for 4 weeks every 6 weeks) [1]. Six weeks later, the patient developed an ischemic left foot and angiography showed embolic distal occlusions of the anterior and posterior tibial artery. Percutaneous transluminal angioplasty and local fibrinolysis led to partial improvement in the ischaemic symptoms; histological analysis from the embolus showed thrombotic material. Transoesophageal colour echocardiography revealed the source of thrombo-embolism as a pedunculated thrombus in the descending aorta (Figure 1). The aorta was otherwise normal without atherosclerosis. Bevacizumab was stopped while IFL therapy was continued. Therapeutic long-term dalteparin was started. Despite this therapy, the left big toe became necrotic and finally had to be amputated. Six weeks later, control echocardiography showed a complete disappearance of the thrombus. Ten weeks after initiating chemotherapy, thoracic CT showed significant reduction in the size of all three lung lesions. Clotting analysis showed normal values for antithrombin, protein C, protein S and plasminogen; negative results for lupus anticoagulant and anticardiolipin antibodies; no factor V Leiden or prothrombin G20210A mutation and normal homocystein serum levels. Thereafter, dalteparin was replaced by oral anticoagulation with phenprocoumon.Keywords
This publication has 5 references indexed in Scilit:
- Vascular Endothelial Growth Factor Localization in the AdultThe American Journal of Pathology, 2006
- Bevacizumab—current status and future directionsAnnals of Oncology, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003
- Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2003